UnknownPhase 4

Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy

China102 participantsStarted 2020-06

Plain-language summary

The study will evaluate the efficacy and safety of two different regimens of anti-VEGF Therapy (OCTA plus OCT guided 3+PRN vs. OCT guided 3+PRN) in Chinese patients with PCV. This study is to provide long-term safety data in the treatment of Chinese patients with PCV.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Anti-angiogenesis drugs (pegaptanib, ranibizumab, bevacizumab),VEGF-Trap;
✕. Anecortave acetate corticosteroids;
✕. Protein kinase C inhibitors, squalamine, siRNA;
✕. PDT, Visudyne® treatment, external beam radiotherapy, local laser photocoagulation, vitrectomy, submacular surgery and transpupillary thermotherapy

What they're measuring

PCV lesion recurrence

Timeframe: 24 months

Trial details

NCT IDNCT04380974

SponsorXiaodong Sun

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-10

Contact for this trial

Xiaodong Sun

+86-02163240090 xdsun@sjtu.edu.cn

View on ClinicalTrials.gov More Polypoidal Choroidal Vasculopathy trials